伊特卡赛肽:治疗慢性肾病继发性甲状旁腺机能亢进新药

郑飞; 张彦丽; 张谦; 巩颖; 顾媛媛; 华国栋; ZHENG Fei; ZHANG Yan-li; ZHANG Qian; GONG Ying; GU Yuan-yuan; HUA Guo-dong

温馨提示：建议您使用Chrome80、火狐74+、IE9+浏览器，当您的浏览器版本过低，可能会影响部分功能正常使用。

主办：天津药物研究院中国药学会

微信公众号

网站二维码

2025年6月14日 8:32 星期六

首页 > 过刊浏览>2017年第40卷第3期 >2017,40(3):428-432. DOI:10.7501/j.issn.1674-6376.2017.03.028

伊特卡赛肽:治疗慢性肾病继发性甲状旁腺机能亢进新药

郑飞
郑飞
北京中医药大学东方医院药学部, 北京 100078
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
张彦丽
张彦丽
北京中医药大学东方医院药学部, 北京 100078
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
张谦
张谦
北京中医药大学东方医院药学部, 北京 100078
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
巩颖
巩颖
北京中医药大学东方医院药学部, 北京 100078
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
顾媛媛
顾媛媛
北京中医药大学东方医院药学部, 北京 100078
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
华国栋
华国栋
北京中医药大学东方医院药学部, 北京 100078
通讯作者.
Email: zhaojhuagd@126.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Etelcalcetide: A new drug for secondary hyperparathyroidism of chronic kidney disease

ZHENG Fei
ZHENG Fei
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
ZHANG Yan-li
ZHANG Yan-li
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
ZHANG Qian
ZHANG Qian
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
GONG Ying
GONG Ying
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
GU Yuan-yuan
GU Yuan-yuan
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
HUA Guo-dong
HUA Guo-dong
Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China
Contact Author.
Email: zhaojhuagd@126.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：2017-04-08

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

伊特卡赛肽 ; 新型二代拟钙剂 ; 慢性肾病 ; 继发性甲状旁腺机能亢进 ; 甲状旁腺素

[摘要]

伊特卡赛肽（商品名为Parsabiv^TM）是安进公司开发的新型二代拟钙剂，主要用于治疗慢性肾病继发性甲状旁腺机能亢进。伊特卡赛肽通过直接与钙感应受体结合来降低血钙浓度，还可以降低甲状旁腺素的水平。欧盟于2016年11月批准注射用伊特卡赛肽用于慢性肾病继发性甲状旁腺机能亢进的透析患者。介绍该药的药理作用、药动学、临床试验及不良反应研究概况。

[Key word]

Etelcalcetide ; second generation calcimimetic agent ; chronic kidney disease ; secondary hyperparathyroidism ; parathyroid

[Abstract]

Etelcalcetide (Parsabiv^TM) is a second generation calcimimetic agent newly developed by Amgen, mainly used for the treatment of secondary hyperparathyroidism. Etelcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor, but also reduces the parathyroid hormone level. The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection. This paper summarized the pharmacological effects, pharmacokinetics, clinical trials, and adverse reaction of Etelcalcetide.

[中图分类号]

[基金项目]

引用本文 / Get Citation

郑飞,张彦丽,张谦,巩颖,顾媛媛,华国栋.伊特卡赛肽:治疗慢性肾病继发性甲状旁腺机能亢进新药[J].药物评价研究,2017,40(3):428-432

分享 / Share

文章指标 / Article Metrics

点击次数: 1335

下载次数: 2329

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2016-12-26

在线发布日期: 2017-04-08

[1] Cozzolino M, TomLinson J, Walsh L, et al. Emerging drugs forsecondary hyperparathyroidism[J]. Expert Opin Emerg Drugs, 2015, 20(2):197-208.

[2] 刘晓琰, 陆国红, 汤璐敏. 中药治疗慢性肾病研究现状[J]. 中国药师, 2007, 10(6):590-592.

[3] Rodriguez M, Goodman W G, Liakopoulos V, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism:a 10 year evidence review[J]. Semin Dial, 2015, 28(5):497-507.

[4] 李敏, 李峰, 高鑫. 慢性肾病患者继发性甲状旁腺功能亢进的外科治疗现状[J]. 实用医药杂志, 2016, 33(7):653-655.

[5] 仇方忻, 史新正, 李浩. 等. 维持性血液透析合并继发性甲状旁腺功能亢进患者骨代谢及骨密度变化[J]. 中国血液净化, 2016, 15(7):332-335.

[6] Amgen. European Commission approves Parsabiv^TM (Etelcalcetide) for the treatment of secondary hyperparathyroidism in adultson hemodialysis[EB/OL]. (2016-11-11)[2016-12-25]. http://www.amgen.com/media/news-releases/2016/11/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis/.

[7] Committee for Medicinal Products for Human Use (CHMP). Parsabiv:Etelcalcetide-summary of opinion (initial authorisation). hemodialysis[EB/OL]. (2016-10-19)[2016-12-25]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003995/human_med_002037.jsp&mid=WC0b01ac058001d124.

[8] Amgen. Amgen submits marketing authorization application fornovel intravenous calcimimeticet Elcalcetide (AMG 416) to the European Medicines[EB/OL]. (2016-09-02)[2016-12-25]. http://www.amgen.com/media/news-releases/2015/08/amgen-submits-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416/.

[9] Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416(Velcalcetide), a novel peptide agonist of the calcium-sensingreceptor, for the treatment of secondary hyperparathyroidism inhemodialysis patients[J]. J Pharmacol Exp Ther, 2013, 346(2):229-240.

[10] Alexander S T, Hunter T, Walter S, et al. Critical cysteine residuesin both the calcium-sensing receptor and the allostericactivator AMG 416 underlie the mechanism of action[J]. Mol Pharmacol, 2015, 88(5):853-865.

[11] Walter S, Baruch A, Alexander S T, et al. Comparison of AMG416 and cinacalcet in rodent models of uremia[J]. BMC Nephrol, 2014, 15(1):81.

[12] Martin K J, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), anovel peptide agonist of the calcium-sensing receptor, reducesserum parathyroid hormone and FGF23 levels in healthy malesubjects[J]. Nephrol Dial Transplant, 2014, 29(2):385-392.

[13] Yokoyama K, Fukagawa M, Shigematsu T, et al. A novel intravenouscalcimimetic, ONO-5163(etelcalcetide):a multicenter, single and multiple dose study in Japanese hemodialysis patientswith secondary hyperpara-thyroidism[J]. Nephrol Dial Transplant, 2016, 31(S1):i462.

[14] Shen J, Xiao J, Pickthorn K, et al. A pharmacokinetic/pharmacodynamics model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects[J]. J Clin Pharmacol, 2014, 54(10):1125-1133.

[15] Chen P, Melhem M, Xiao J, et al. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis[J]. J Clin Pharmacol, 2015, 55(6):620-628.

[16] Subramanian R, Zhu X, Hock M B, et al. Pharmacokinetics, biotransformation, and excretion of[¹⁴C] Etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis[J]. Clinic Pharmacok, 2017, 56(2):179-192.

[17] Edson K Z, Wu B M, Iyer A, et al. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timingof its dosing[J]. Kid Int Rep, 2016, 1(1):24-33.

[18] Subramanian R, Zhu X, Kerr S J, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a noveld-amino acid peptide agonist of the calcium-sensing receptor AMG 416(Etelcalcetide)[J]. Drug Metab Dispos, 2016, 44(8):1319-1331.

[19] Bell G, Huang S, Martin K J, et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 forthe treatment of secondary hyperparathyroidism in hemodialysis patients[J]. Curr Med Res Opin, 2015, 31(5):943-952.

[20] Bushinsky D A, Block G A, Martin K J, et al. Treatment of secondary hyperparathyroidism:results of a phase 2 trial evaluatingan intravenous peptide agonist of the calcium-sensing receptor[J]. Am J Nephrol, 2015, 42(5):379-388.

[21] Martin K J, Pickthorn K, Huang S, et al. AMG 416(velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients[J]. Kidney Int, 2014, 85(1):191-197.

[22] Bushinsky D A, Block G A, Cheng S, et al. One year efficacy and safetyof intravenous (IV) etelcalcetide (AMG 416) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT)[J]. Nephrol Dial Transplant, 2016, 31(S1):i13-i14.

[23] Fukagawa M, Yokoyama K, Shigematsu T, et al. Efficacy and safetyof a novel intravenous calcimimetic, ONO-5163(Etelcalcetide) in Japanese hemodialysis patients with secondary hyperparathyroidism:results of a placebo controlled phase III study[J]. Nephrol Dial Transplant, 2016, 31(S1):i460.

[24] Martin K, Block G, Cheng S, et al. Comparison of the efficacyand safety of intravenous (IV) etelcalcetide (AMG 416) and oralcinacalcet (CIN) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT)[J]. J Am Soc Nephrol,. 2015, 26:B9.

[25] European Medicines Agency. Parsabiv:summary of product characteristics[EB/OL]. (2016-11-28)[2016-12-25]. http://www.medicines.org.uk/emc/medicine/32575.